Dr Ana Guijarro Cascales (Hospital Universitario Fundacion Alcorcon, Spain) examined the national registry of Spain from 2011-2015 for the impact of the number of radical cystectomies performed per hospital on 90-day mortality. In the literature, 90-day mortality is variable but generally thought to relate to number of patients treated per year, and reported to be 2.3-7.9% [1]. The majority of hospitals do less than 10 radical cystectomies per year (191/196), with only 5 hospitals performing more than 38 per year. Across all Spanish hospitals, median mortality at 30, 60, and 90 days was respectively 2.9%, 5.2%, and 6.5%.
However, at the five higher volume centres (38+ radical cystectomies per year) the mortality rate at 90 days was just 3.3%. By extrapolation, every additional 10 radical cystectomies performed per year in a given hospital will decrease 90-day mortality by 20% (P<0.001). These data should support the centralisation of radical cystectomy surgery.
Posted on
Previous Article
« Cytoreductive radical prostatectomy: LoMP trial results Next Article
DCIS: de-escalation of (adjuvant) therapy »
« Cytoreductive radical prostatectomy: LoMP trial results Next Article
DCIS: de-escalation of (adjuvant) therapy »
Table of Contents: EAU 2019
Featured articles
Prostate Cancer
Barentsz Trial – Bi-parametric MRI versus multi-parametric MRI
Enzalutamide plus ADT improves outcomes for metastatic hormone-sensitive prostate cancer
Prostate cancer active surveillance: Better patient risk stratification and use of imaging
The role of pelvic lymph node dissection in prostate cancer: Extended vs standard
When to use imaging and imaging-guided therapies
Radioguided surgery is the future?
Bladder Cancer
Largest safety study of its kind with atezolizumab in metastatic bladder cancer
Bladder cancer risk and early detection
Consensus treatment pathway for patients with limited pelvic lymph node involvement in otherwise localised bladder cancer
FGFR3 gene mutation: Favourable prognostic impact in bladder cancer
Bladder cancer in young patients
Spanish study directly links surgical volume with mortality in bladder cancer patients undergoing cystectomy
Updated interim results of phase 2 trial of pembrolizumab for high-risk NMIBC unresponsive to BCG
Robot-assisted radical cystectomy or open radical cystectomy?
Renal Transplantation and Renal Cell Carcinoma
Andrology
Microdissection testicular sperm extraction (microTESE)
Male infertility/Premature ejaculation
Testosterone replacement therapy: Safe and maybe even protective
Focus on treatment of erectile dysfunction and Peyronie’s disease
Penile prosthesis implantation
Functional Urology
Decision aids are too difficult for patients
Lower Urinary Tract Symptoms
The Urodynamics for Prostate Surgery Trial
Minimally invasive surgical techniques must compete against pharmacotherapy in benign prostate hyperplasia (BPH)
Related Articles
November 16, 2021
Acute urinary retention tied to increased risk of certain cancers
August 21, 2020
PSMA PET-CT staging is 27% more accurate
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy